Please login to the form below

Not currently logged in
Email:
Password:

Cipla appoints Novartis’ Subhanu Saxena as CEO

Was previously head of global product strategy and commercialisation at Swiss pharma firm

Subhanu Saxena has left Novartis to join India-based generics company Cipla as its new CEO.

Saxena was previously head of global product strategy and commercialisation at Novartis, where he was also part of the Swiss pharma giant's executive committee, and will take up his new position from February 1, 2013.

Prior to this most recent position at Novartis, Saxena was CEO and country president of Novartis UK.

He also has wide non-healthcare experience, working with companies such as Citicorp, the Boston Consulting Group and PepsiCo across markets in Europe, North America, Africa and Asia.

Cipla's chair Dr Yusuf Hamied said: “We are delighted to have found such a good match for Cipla in Subhanu. Cipla has a strong vision for the future. I am confident Subhanu will build on Cipla's core values to deliver the next phase of growth, competitiveness and return on shareholder value.”

Saxena joins at a time of growth for Cipla, with the company recently announcing plans to expand its footprint in Africa.

Cipla has also been busy challenging big pharma patents, and in September won a four-year battle to market its own version of Roche's cancer drug Tarceva (erlotinib). The verdict followed another recent win, that this time saw it granted permission to market a generic version of Pfizer's Sutent (sunitinib malate) after challenging the drug's patent.

26th November 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics